Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.62 |
| ▸ | BAD | Q92934 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalic Acid SCHEMBL10780545 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| SCHEMBL38562 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| Biphenyl SCHEMBL27749501 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| Biphenyl SCHEMBL5186249 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| SCHEMBL7155730 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| Benzene SCHEMBL28431643 | 0.97 | EGFR (0.72) | EGFRTSHRDAONAPRTTP53 | |
| SCHEMBL1584121 | 0.95 | EGFR (0.69) | EGFRTSHRDAONAPRTTP53 | |
| Biphenyl SCHEMBL9650627 | 0.95 | EGFR (0.69) | EGFRTSHRDAONAPRTTP53 | |
| Methane SCHEMBL20584283 | 0.95 | EGFR (0.69) | EGFRTSHRDAONAPRTTP53 | |
| SCHEMBL2596283 | 0.95 | EGFR (0.69) | EGFRTSHRDAONAPRTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050419-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2024-02-15 | — | — | US | claimed |
| US-20220184117-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | BORODY THOMAS JUJIS (AU) | 2022-06-16 | — | — | US | claimed |
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | claimed |
| EP-0899266-B1 | Process for the production of benzoxazinones | CIBA SC HOLDING AG (CH) | 2003-01-15 | — | — | EP | claimed |
| US-6040443-A | Process for the production of benzoxazinones | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-03-21 | — | — | US | claimed |
| EP-0899266-A1 | Process for the production of benzoxazinones | Ciba SC Holding AG (CH) | 1999-03-03 | — | — | EP | claimed |
| JP-59174849-A | — | — | None | — | — | JP | disclosed |
| US-20240050419-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2024-02-15 | — | — | US | disclosed |
| CN-114644583-B | Indole derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-06 | — | — | CN | disclosed |
| US-11833140-B2 | Compositions and methods for treating, ameliorating and preventing H. pylori infections | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20220184117-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | BORODY THOMAS JUJIS (AU) | 2022-06-16 | — | — | US | disclosed |
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | disclosed |
| CN-111629728-A | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | 科尔沃斯制药股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-4335054-A | Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | disclosed |
| US-4335055-A | Process for the preparation of alkenylbenzene derivatives or alkenylnaphthalene derivatives | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | disclosed |
| US-4214099-A | Intermediates for synthesis of precursors for prostaglandins | PFIZER INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4122093-A | Process for preparing a lactone | PFIZER INC. (US) | 1978-10-24 | — | — | US | disclosed |
| US-4029835-A | MADE BY PRESSING AND HEATING A MIXED WEB OF TWO AROMATIC POLYAMIDES | MITSUBISHI RAYON CO., LTD. (JA) | 1977-06-14 | — | — | US | disclosed |
| US-3992438-A | Novel prostaglandin intermediates | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3943151-A | Prostaglandin intermediates | PFIZER INC. (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184117-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | ATP1A2, ATP4A, ATP1A3 | EGFR 4754/4885TSHR 3723/4885DAO 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.